Characteristic | N (%) |
---|---|
Gender | Â |
Female | 40 (43.5) |
Male | 52 (56.5) |
Age, years | Â |
Mean ± SD | 11.4 ± 3.6 |
Median (range) | 11.0 (6.0–18.0) |
Age group | Â |
Children | 62 (67.4) |
Adolescents | 30 (32.6) |
Hospital | Â |
NOC | 60 (65.2) |
SQUH | 22 (23.9) |
SQCCCRC | 10 (10.9) |
Diagnosis | Â |
Leukaemia | 38 (41.3) |
Lymphoma | 25 (27.2) |
Solid tumour | 23 (25.0) |
Brain tumour | 6 (6.5) |
Time since diagnosis, months | Â |
< 1 | 66 (71.7) |
1–2 | 19 (20.7) |
2–3 | 7 (7.6) |
Type of cancer diagnosis | Â |
Relapse | 9 (9.8) |
New | 83 (90.2) |
Cancer risk* | Â |
Not applicable | 6 (6.5) |
Standard/low | 18 (19.6) |
Intermediate | 26 (28.3) |
High | 42 (45.7) |
Cancer stage | Â |
Not applicable | 39 (42.4) |
I | 7 (7.6) |
II | 8 (8.7) |
III | 18 (19.6) |
IV | 20 (21.7) |
Treatment type | Â |
Chemotherapy alone | 56 (60.9) |
Chemotherapy and radiotherapy | 12 (13.0) |
Chemotherapy and surgery | 9 (9.8) |
Chemotherapy, radiotherapy, and surgery | 10 (10.9) |
Chemotherapy and transplant | 5 (5.4) |
Aware of diagnosis | Â |
Yes | 27 (29.3) |
No | 65 (70.7) |